K-PAX Vitamin’s formulas are based on many years of scientific research. Beginning in 2001, Dr. Jon Kaiser developed a formula of vitamins, amino acids and antioxidants in an effort to support the immune systems of the hundreds of HIV(+) patients in his care.
Based on the strongly positive effect on immune function he was observing in these patients, Dr. Kaiser enlisted substantial funding from a large pharmaceutical company (Bristol-Myers Squibb) to perform a double-blinded, placebo-controlled research study of our Immune formula in people with HIV/AIDS. The success of this study led to the launching of K-PAX Vitamins and the performance of several additional clinical trials with our micronutrient products.
“Micronutrient Supplementation Increases CD4 Count in HIV-infected Individuals on HAART: A Prospective, Double-Blinded, Placebo-Controlled Trial”
The results of this study concluded that the micronutrient formula tested (the prototype of K-PAX Immune) significantly improved CD4 cell count reconstitution in HIV-infected patients taking HAART. The intervention was well-tolerated and appears to be safe when combined with antiretroviral therapy.
“A Prospective, Proof-of-concept Investigation of KPAX002 in Chronic Fatigue Syndrome (CFS)”
(Int J Clin Exp Med 2015;8(7):11064-11074)
The results of this study concluded that KPAX002 (methylphenidate plus a mitochondrial support nutrient formula) demonstrated improvement in fatigue and concentration disturbance symptoms in multiple analyses. Two key subgroups of patients whose response approached statistical significance were identified. These included study subjects with more severe symptoms and patients with both fatigue and pain.
The K-PAX Energy Support Program is an over-the-counter version of this same concept. It consists the same mitochondrial support nutrients plus a low dosage of caffeine and is designed to help increase energy and mental alertness.
Methylphenidate plus Mitochondrial Support Nutrients as a Treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): A Prospective, Randomized Trial
“A Prospective Open-Label Clinical Trial of Methylphenidate plus KPAX002 in Patients with Gulf War Illness and Concentration Disturbances”